December 22, 2023
Healthtech, why we need you to help us push it forward

Health is known for its complexity in product development, stakeholders and regulations. With your validation through the survey and programmes, we would like to work with you on how we can improve the Healthtech sector in the Netherlands.
At Techleap.nl we’ve seen that when we come together as an ecosystem to focus on the specific challenges that industries or sectors face, we can make more of an impact together. As an organisation, our efforts will be focused on working with the ecosystem to collaboratively build solutions to help accelerate the growth of Healthtech startups.
This is the beginning of that journey as we look to garner deeper insights which you can help to provide via the survey below or share with your network. The next steps after this will be to assess the data, report it back to the ecosystem and then push forward with a range of programmes, resources and events to help solve the challenges found.
In our initial research, Techleap.nl has identified possible acceleration through the following ways to collaborate:
If you’re wondering how we categorise a Healthtech company, here’s our definition: a Healthtech startup is a company working in medicine that uses technology to prevent, diagnose and treat human diseases. This can be broken down further into the fields of biotechnology, medical devices, health platforms, and pharmaceuticals.
When selecting a particular sector or theme to work on we use a set of criteria and data points. In short, we look at such things as number of startups, amount invested in the sector, the problems experienced, national expertise, and importantly whether we feel value can be added by addressing the sector with our efforts.
With Healthtech we see not only the relevance due to the pandemic but also from an objective standpoint. In 2020, €425M was invested in the market with a higher than average deal size when compared to the national average (€8.0M Healthtech v €5.9M national average for 2020). We noticed a considerable increase in average round size but not a widespread amount of money filtering through the ecosystem to all stages. This poses a possible threat to the current funnel of startups coming through that will reach scaleup status as the overall number of companies raising has reduced. We also see that the sector struggles to compete financially with its European ecosystem counterparts.
However, we see an environment nationally that can support these companies to make even more of a difference if mobilised.
Do you have expertise in the Healthtech sector in the Netherlands, and/or feel like you can contribute towards better impact in this domain? Please fill out the form.
In this report you will find out: